JP2019504892A - 癌治療のための改変哺乳類細胞 - Google Patents

癌治療のための改変哺乳類細胞 Download PDF

Info

Publication number
JP2019504892A
JP2019504892A JP2018560705A JP2018560705A JP2019504892A JP 2019504892 A JP2019504892 A JP 2019504892A JP 2018560705 A JP2018560705 A JP 2018560705A JP 2018560705 A JP2018560705 A JP 2018560705A JP 2019504892 A JP2019504892 A JP 2019504892A
Authority
JP
Japan
Prior art keywords
cell
promoter
pharmaceutical composition
nucleic acid
modified mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504892A5 (enExample
Inventor
ファン，シャオフー
チャン，ファンリャン
ジュアン，チーチュアン
ワン，ピンヤン
ユ，ジエ
ヘ，シアン
ワン，リン
ハオ，ジャーイン
ヤン，レイ
Original Assignee
ナンキン レジェンド バイオテック カンパニー リミテッド
ナンキン レジェンド バイオテック カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナンキン レジェンド バイオテック カンパニー リミテッド, ナンキン レジェンド バイオテック カンパニー リミテッド filed Critical ナンキン レジェンド バイオテック カンパニー リミテッド
Publication of JP2019504892A publication Critical patent/JP2019504892A/ja
Publication of JP2019504892A5 publication Critical patent/JP2019504892A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018560705A 2016-02-04 2017-01-26 癌治療のための改変哺乳類細胞 Pending JP2019504892A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/073489 2016-02-04
CN2016073489 2016-02-04
PCT/CN2016/087855 WO2017133175A1 (en) 2016-02-04 2016-06-30 Engineered mammalian cells for cancer therapy
CNPCT/CN2016/087855 2016-06-30
PCT/CN2017/072723 WO2017133633A1 (en) 2016-02-04 2017-01-26 Engineered mammalian cells for cancer therapy

Publications (2)

Publication Number Publication Date
JP2019504892A true JP2019504892A (ja) 2019-02-21
JP2019504892A5 JP2019504892A5 (enExample) 2020-03-05

Family

ID=59499323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560705A Pending JP2019504892A (ja) 2016-02-04 2017-01-26 癌治療のための改変哺乳類細胞

Country Status (5)

Country Link
US (1) US20190038671A1 (enExample)
EP (1) EP3411079A4 (enExample)
JP (1) JP2019504892A (enExample)
CN (1) CN108883202A (enExample)
WO (2) WO2017133175A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544075A (ja) * 2019-08-01 2022-10-17 メモリアル スローン ケタリング キャンサー センター 改良された免疫療法のための細胞およびその使用
JP2023509999A (ja) * 2020-01-14 2023-03-10 アダプティミューン・リミテッド がんまたは腫瘍の治療の方法
JP2023540023A (ja) * 2020-08-24 2023-09-21 シャリテ－ウニベルジテーツメディツィン ベルリン Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
KR20240024328A (ko) 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
WO2018152572A1 (en) * 2017-02-21 2018-08-30 The University Of Adelaide T cells expressing chemokine receptors for treating cancer
JP2020516654A (ja) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US20210095029A1 (en) * 2017-04-19 2021-04-01 University Of Southern California Compositions and methods for treating cancer
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
US12385061B2 (en) 2017-09-08 2025-08-12 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
CA3079076A1 (en) * 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
AU2019221324A1 (en) * 2018-02-15 2020-09-03 The National Institute for Biotechnology in the Negev Ltd. Tumor environment-specific expression of chimeric antigen receptors
JP7154634B2 (ja) * 2018-03-13 2022-10-18 国立大学法人大阪大学 腫瘍免疫賦活剤
WO2019199689A1 (en) * 2018-04-09 2019-10-17 The Trustees Of The University Of Pennsylvania Methods and compositions comprising a viral vector for expression of a transgene and an effector
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
CN108913718A (zh) * 2018-07-20 2018-11-30 苏州茂行生物科技有限公司 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用
CN108949825A (zh) * 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
JP7558151B2 (ja) * 2018-09-05 2024-09-30 アダプティミューン・リミテッド Ｔ細胞改変
WO2020052542A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
TW202035685A (zh) 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
CA3116412A1 (en) 2018-10-31 2020-05-07 Humanigen, Inc. Materials and methods for treating cancer
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
US20210369776A1 (en) * 2018-12-06 2021-12-02 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
AU2020218546A1 (en) * 2019-02-08 2021-09-09 Dna Twopointo Inc. Transposon-based modifications of immune cells
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
US20220088075A1 (en) * 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020181221A1 (en) * 2019-03-07 2020-09-10 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
WO2020219504A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2021016598A1 (en) * 2019-07-25 2021-01-28 Immunowake Inc. Methods of measuring cell-mediated killing by effectors
WO2021041920A1 (en) * 2019-08-28 2021-03-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
JP7752424B2 (ja) * 2019-10-22 2025-10-10 アロプレックス バイオセラピューティクス シリアルキラーｔ細胞集団のインビトロ活性化及び拡大、ならびに腫瘍細胞殺傷細胞を有するがん患者の受動免疫化のための組成物及び方法
CN115297873A (zh) * 2019-11-08 2022-11-04 梅约医学教育与研究基金会 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
MX2022010549A (es) 2020-02-26 2022-11-16 Biograph 55 Inc Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.
WO2021197430A1 (en) * 2020-04-01 2021-10-07 Nanjing Legend Biotech Co., Ltd. Compositions and methods for reducing graft rejection in allogeneic cell therapy
WO2022005994A1 (en) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center C825 expressing immune cells and diagnostic uses thereof
WO2022012680A1 (en) 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
AU2021368557A1 (en) * 2020-10-27 2023-06-08 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
US20240285760A1 (en) * 2021-06-24 2024-08-29 Georgia Tech Research Corporation Methods and compositions for remote control of t cell therapies by thermal targeting
CN113789299B (zh) * 2021-10-18 2023-03-24 新鲁细胞生物科技(海南)有限公司 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法
TW202426477A (zh) * 2022-10-07 2024-07-01 美商聖堤生物科技股份有限公司 經武裝之嵌合受體及其使用方法
WO2024107410A1 (en) * 2022-11-14 2024-05-23 The Board Of Trustees Of The Leland Stanford Junior University Cd39 selection for cytotoxicity of genetically engineered t regulatory cells
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival
WO2025081190A1 (en) * 2023-10-12 2025-04-17 Georgia Tech Research Corporation Image guided car t cell therapy to treat brain tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2014134165A1 (en) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
WO2015188119A1 (en) * 2014-06-06 2015-12-10 Bluebird Bio, Inc. Improved t cell compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215964A (en) * 1991-06-03 1993-06-01 Immunobiology Research Institute, Inc. Peptides useful in regulating the immune and nervous systems
AU1377299A (en) * 1997-11-03 1999-05-24 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP1984505B1 (en) * 2006-01-13 2019-12-25 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
WO2016014530A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016210129A1 (en) * 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2014134165A1 (en) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
WO2015188119A1 (en) * 2014-06-06 2015-12-10 Bluebird Bio, Inc. Improved t cell compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH，２０１３年，VOL.19, NO.20，PP.5636-5646, JPN6021006274, ISSN: 0004608014 *
血液フロンティア, 2016 NOV, VOL.26 NO.11, P.86-89, JPN6021006276, ISSN: 0004450935 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544075A (ja) * 2019-08-01 2022-10-17 メモリアル スローン ケタリング キャンサー センター 改良された免疫療法のための細胞およびその使用
JP7668261B2 (ja) 2019-08-01 2025-04-24 メモリアル スローン ケタリング キャンサー センター 改良された免疫療法のための細胞およびその使用
JP2023509999A (ja) * 2020-01-14 2023-03-10 アダプティミューン・リミテッド がんまたは腫瘍の治療の方法
JP2023540023A (ja) * 2020-08-24 2023-09-21 シャリテ－ウニベルジテーツメディツィン ベルリン Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞
JP7849891B2 (ja) 2020-08-24 2026-04-22 シャリテ－ウニベルジテーツメディツィン ベルリン Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞

Also Published As

Publication number Publication date
WO2017133633A1 (en) 2017-08-10
EP3411079A1 (en) 2018-12-12
US20190038671A1 (en) 2019-02-07
CN108883202A (zh) 2018-11-23
EP3411079A4 (en) 2019-10-30
WO2017133175A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
US20190038671A1 (en) Engineered mammalian cells for cancer therapy
WO2020228825A1 (en) Engineered immune cells comprsing a recognition molecule
US12624081B2 (en) Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
JP2023052446A (ja) 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
JP2022043043A (ja) 免疫細胞の有効性および増大を改善する方法
WO2020147708A1 (en) Chimeric receptor polypeptides and uses thereof
US20190375815A1 (en) Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US20180133296A1 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor?expressing cells
JP2020534871A (ja) キメラエンガルフメント受容体分子および使用方法
US20210038659A1 (en) Combination therapy using a chimeric antigen receptor
IL283218B1 (en) Methods of dosing engineered t cells for the treatment of b cell malignancies
TW202321287A (zh) 特異性靶向間皮素之經工程改造之免疫細胞及其用途
EP4484563A1 (en) Viral vector and producer cell
EP4626473A1 (en) Humanized anti-hla-g chimeric antigen receptors and uses thereof
CA3243771A1 (en) CAR ANTI-BCMA TO TARGET IMMUNITY-RELATED DISORDERS, COMPOSITIONS AND RELATED METHODS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005